BTK Inhibitor Synergizes With CD19‐Targeted Chimeric Antigen Receptor‐T Cells in Patients With Relapsed or Refractory B‐Cell Lymphoma: An Open‐Label Pragmatic Clinical Trial

ABSTRACT Background CD19‐targeted chimeric antigen receptor‐T cell (CART19) therapy is clinically effective in patients with relapsed or refractory B‐cell lymphoma (BCL), but treatment failure and recurrence need to be overcome. Preclinical studies demonstrated that Bruton tyrosine kinase inhibitor...

Full description

Bibliographic Details

Published in:	Cancer Medicine
Main Authors:	Wenjing Luo, Yinqiang Zhang, Chenggong Li, Jia Xu, Zhuolin Wu, Xindi Wang, Yun Kang, Danying Liao, Haiming Kou, Wei Xie, Wei Xiong, Jun Deng, Heng Mei, Yu Hu
Format:	Article
Language:	English
Published:	Wiley 2025-10-01
Subjects:	B‐cell lymphoma Bruton tyrosine kinase inhibitor chimeric antigen receptor‐T cell pragmatic clinical trial
Online Access:	https://doi.org/10.1002/cam4.71321